Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.)
·
- Prescription status not stated
- Breathing, airways, allergies and cough
- Active substance
- Beclometasone;formoterol
- Made by
- Chiesi Farmaceutici S.p.A.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist (for effects on symptoms control and prevention of exacerbations see section 5.1).
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
BulgariaNo exact match for this strength and form
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Chiesi Farmaceutici S.p.A. |
|---|---|
| Active substance | Beclometasone;formoterol |
| Used in | Breathing, airways, allergies and cough |
| Classification | R03AL09 · Breathing, airways, allergies and cough |
| Authorised on | 2018-04-23 |
| Last updated by the regulator | 2025-03-18 |
| EMA product number | EMEA/H/C/004836 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).